The abstract is read at the publisher; the summary is JClub's.
High MYBL2 expression is critical for triple-negative breast cancer stem/progenitor cell self-renewal and DNA repair, and MYBL2 downregulation impairs stemness in vitro and in vivo.
- Why it matters: TNBC has poor outcomes partly because therapy-resistant stem/progenitor cells drive metastasis, and MYBL2’s role in these cells is not well defined.
- What they did: Using inducible MYBL2 downregulation in TNBC cell lines and patient-derived models, the study tested stemness and DNA repair functions and assessed sensitivity to Polθ inhibitors, then evaluated Polθ plus ATR inhibitor combinations in vitro, ex vivo, and in vivo.
- The result: Polθ inhibitor sensitivity is higher in MYBL2-high stem/progenitors and is lost after MYBL2 downregulation; dual Polθ/ATR inhibition further enhances sensitivity, supporting MYBL2 as a biomarker for stratifying TNBC patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.